Generics 24

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Ibrutinib manufacturers

24 products found

Filters

24 products found

ibrutinib

Tablets 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
FDA, EU GMP, ANVISA, Libya, Saudi Arabia, South Korea
Unavailable markets
Saudi Arabia , Vietnam
Manufacturer #11907
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products for 20+ years. Key production lines include Rx, OTC, medical devices, and cosmetics. The company's production lines are EU GMP-compliant. The company owns branches in the EU, North America, and Africa.

Manufacturer usually replies in 8 days

ibrutinib

Capsules, hard liquid 140 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
MA’s Granted
Manufacturer #21467

Manufacturer usually replies in 9 days

ibrutinib

Tablets, film coated 140 mg, 280 mg, 420 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 9 days

ibrutinib

Tablets 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q3 2027
Manufacturer #519

Manufacturer usually replies in 6 days

ibrutinib

Tablets 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #614
A pharmaceutical manufacturer based in Europe selling its products in Europe and worldwide for 10+ years. Main dosage forms include injectable and oral dosage forms. The company's production lines are EU GMP-compliant. The main therapeutic area is oncology.

Manufacturer usually replies in 7 days

ibrutinib

Tablets 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP, ANVISA
Comments
Dossier status : Early stage
Manufacturer #313

A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, North America, LATAM, and Asia for 10+ years. Key production lines are Rx, OTC, and nutraceuticals. Main therapeutic areas include the respiratory system, dermatology, and cardiovascular system. The company possesses several branches in LATAM

Manufacturer usually replies in 7 days

ibrutinib

Tablets, film coated 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Iran , Vietnam
Available for
Licensing with supply
Comments
Indication: Leukemia; Status: Q2 2025 Under Development
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 11 days

ibrutinib

Capsules 140 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Costa Rica
Manufacturer #1338

Manufacturer usually replies in 7 days

ibrutinib

Capsules 140 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #9406

Manufacturer usually replies in 7 days

ibrutinib

Tablets 140 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #22283

Manufacturer usually replies in 4 days

ibrutinib

Tablets, film coated 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
Turkey
GMP approvals
EU GMP
Manufacturer #2722
It originally entered the pharmaceutical industry in 1987, when it introduced blood derivative products to Europe and became the exclusive distributor for prominent European brands. Oncology, hematology, dermatology, radiology, rheumatology, immunology, and OTC products are the seven main therapeutic fields.

Manufacturer usually replies in 6 days

ibrutinib

Capsules 140mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina, Brazil, Pakistan, Paraguay, Peru, Uruguay, WHO, PICS
Manufacturer #16112

Manufacturer usually replies in 6 days

ibrutinib

Capsules 140mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina
Manufacturer #16199
One of the largest and biggest names in the pharmaceutical industry. The company has a network all across the globe. They are known to be partnering with similar companies for a very long time.

Manufacturer usually replies in 9 days

ibrutinib

Capsules 140 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Bangladesh
GMP approvals
WHO
Manufacturer #16099

Manufacturer usually replies in 6 days

ibrutinib

Tablets 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, EU GMP, WHO, MHRA
Manufacturer #16394

Manufacturer usually replies in 12 days

ibrutinib

Capsules 140 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
Argentina
GMP approvals
PICS
Manufacturer #16454
A pharmaceutical company based in South America with 15+ years of experience in a drug market. More than 40 products in 25+ countries: LATAM; Wester, Southern and South-eastern Asia. Company’s therapeutic areas consist of products that can used in such areas as: urology, oncology, rare diseases and more.

Manufacturer usually replies in 7 days

ibrutinib

Tablets 140 mg, 280 mg, 420 mg, 560 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, Canada
Manufacturer #16394

Manufacturer usually replies in 12 days

ibrutinib

Capsules 140 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17753

Manufacturer usually replies in 10 days

ibrutinib

Capsules 140 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
PICS
Registered in
Argentina
Available for
Licensing with supply, Distribution only
Manufacturer #15733
One of the leading manufacturers in cosmetic and medicinal products in the South American Continent. The company has been committed since 1990-is to developing and manufacturing high-quality products that allow healing and improve someone’s life. They are a major exporter of its therapies to different regions such as Latin America and Asia. Medicine is manufactured for pain, gastroenterology, hepatology, and cardiology.

Manufacturer usually replies in 17 days

ibrutinib

Capsules 40 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19912

Manufacturer usually replies in 18 days

Want to view all 24 products? Create your free account today!

Ibrutinib Manufacturers

Ibrutinib is commonly sold under the brand name Ibrutinib. It was approved by FDA for its efficiency in treating neoplastic diseases, specifically mantle cell lymphoma, chronic lymphocytic leukemia, and Walden Strom’s macroglobulinemia. This pharmaceutical drug is characterized as kinase inhibitors or Antineoplastics. Ibrutinib is created in tablet and capsule form for oral consumption, which has to be taken as a single dose per day. It is mandatory to take the dose as directed by the doctor without increasing or decreasing it. Ibrutinib has some adverse effects which may warrant immediate attention. It may cause bleeding externally or internally, therefore one should make sure and consult the doctor if they experience symptoms like blood in the vomitus or blood in the cough. This pharmaceutical substance may induce a deficiency in the immune system due to which the patient may become prone to infections. Other side effects include dysentery, Vomiting, Headache, shivering in hands, compromised urination, and blurred vision. The intake of this medicine during pregnancy can affect the growth of the fetus and may produce anomalies in the fetus' organs. One should not get pregnant if taking this pharmaceutical substance or breastfeeding as the drug may get transferred to the child via breast milk. It is contraindicated in people who are allergic, undergoing anticoagulant therapy, or suffering from any hematologic disease. Ibrutinib manufacturers, Ibrutinib suppliers, and Ibrutinib distributors have been granted expedited approval for the treatment of leukemia and lymphoma in patients who have had at least one known strategy. MCL (large-cell lymphoma) is a B-cell non-Hodgkin lymphoma that originates in the lymph node's periphery. MCL is frequently detected late in the disease's progression, and it can quickly spread to the bone marrow, liver, liver, the intestinal system. Ibrutinib is used to treat chronic lymphocytic leukaemia (CLL) patients who have received at least one prior treatment. CLL (chronic lymphocytic leukemia) is a malignancy caused either by bone marrow producing too many lymphocytes. Common illnesses and exhaustion are two common complaints. Adults with leukemia and lymphoma who have received at least one prior therapy, individuals with chronic lymphocytic leukemia small lymphocytic carcinoma even without 17p deletion, and adults with Waldenström's macroglobulinemia are all candidates for ibrutinib in the U. S.

How Does Ibrutinib Work?

It works as a BTK (Bruton’s Tyrosine Kinase) blocker by restricting the B-cell proliferation, which takes place when this pharmaceutical substance binds with an amino acid chain called Bruton’s Tyrosine Kinase protein receptor. It usually requires three to six months to cure such diseases, depending upon the stage of malignancy. Ibrutinib is used to treat acute lymphocytic leukemia (CLL) patients who have a 17p deletion. Label CLL with 17p is a form of leukaemia in which one variant of the TP53 gene is deleted, disrupting the tumour suppressor p53. Because the remaining allele is mostly inactive, this kind of leukaemia is resistant to p53-dependent therapies. Waldenstrom's Macroglobulinemia is treated with ibrutinib (WM). Tag WM carcinoma, also known as hermeneutic lymphoma, is a kind of non-Hodgkin lymphoma in which the cancerous cells produce a lot of macroglobulins. The macroglobulin is a polyclonal protein that belongs to the IgM antibody type, and its unrestrained development produces symptoms including excessive bleeding and eyesight and nervous system damage.

The Wholesale Price Ibrutinib

The general cost for this pharmaceutical remedy per unit of 140mg capsule is $519.57 whereas a pack of 90 capsules may cost $15,586. These prices may vary depending on the choice of the seller. Ibrutinib is only accessible as a brand name medicine; there is no generic equivalent presently. Read about the generic Ibrutinib manufacturers, Ibrutinib suppliers, and Ibrutinib distributor’s availability for additional information. Pharmaceutical corporation lists generally support patient assistance programs (PAPs), which provide free or subsidized drugs to reduced, unemployed, or under-insured people who meet certain criteria. Ibrutinib coupons, rebates, savings cards, trial deals, and free samples are all possibilities. Some offers can be downloaded directly from a website, while others need registration, completion of a form, or the collection of a sample from a physician's office. Wholesale price differs according to orders for sale to the wholesalers, distributors, and retailers.

Navigating our Pharmaceutical Marketplace

Trading and business of pharmaceutical medicines have become easier because of internet services, avoiding the hassle, time, and energy to visit the pharmacy. The main concern in online purchasing and selling arises when one faces the risk of double-dealing and duplicity. Pipeline Pharma, a pharmaceutical drug service provider website that will save you from fraud and provide a safe and reliable platform to place your demanded drug, search for a suitable drug seller, or place any query or suggestions you have. Pipelinepharma serves its visitors by providing additional offers and facilities to fulfill the needs and demands of people. All you need to do is enter the pharmaceutical remedy of your choice in the search bar and select the most suitable drug seller by availing of the filtering option.

Establishing Commercial Ties

Pipelinepharma is a flyover in connecting medicinal drug sellers, purchasers, and wholesale manufacturers who are seeking drug suppliers. One can simply connect to numerous such providers around the globe by entering the drug name in the global list of drugs, selecting a suitable city, and placing the proposal. Both the dealers can negotiate a deal by mutual agreement. Pipelinepharma welcomes the license-holders of medicinal drugs to avail the offers we provide.

Quality Assurance

Customer trust and reliance is the primary concern of Pipeline pharma. Therefore, we make it of the utmost importance to assess and validate for any visitor who seeks to proceed either for sale or purchase; the drug quality and its expiry, before having it registered on our forum.